Parker Institute for Cancer Immunotherapy (PICI)
@parkerici.bsky.social
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.
This form of diabetes affects up to 2% of patients on checkpoint inhibitors — and most require ICU care. The findings point to a path forward. (2/2)
→ www.uclahealth.org/news/release...
→ doi.org/10.1172/jci....
→ www.uclahealth.org/news/release...
→ doi.org/10.1172/jci....
Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA study finds
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...
www.uclahealth.org
July 8, 2025 at 5:52 PM
This form of diabetes affects up to 2% of patients on checkpoint inhibitors — and most require ICU care. The findings point to a path forward. (2/2)
→ www.uclahealth.org/news/release...
→ doi.org/10.1172/jci....
→ www.uclahealth.org/news/release...
→ doi.org/10.1172/jci....
Dr. Knudsen's contributions include over 300 peer-reviewed publications and paradigm-shifting discoveries in prostate cancer research.
Congratulations, @drkarenknudsen.bsky.social, and thank you for your unwavering commitment to ending cancer's devastating impact. #PICIatASCO #ASCO2025 (3/3)
Congratulations, @drkarenknudsen.bsky.social, and thank you for your unwavering commitment to ending cancer's devastating impact. #PICIatASCO #ASCO2025 (3/3)
May 31, 2025 at 2:49 PM
Dr. Knudsen's contributions include over 300 peer-reviewed publications and paradigm-shifting discoveries in prostate cancer research.
Congratulations, @drkarenknudsen.bsky.social, and thank you for your unwavering commitment to ending cancer's devastating impact. #PICIatASCO #ASCO2025 (3/3)
Congratulations, @drkarenknudsen.bsky.social, and thank you for your unwavering commitment to ending cancer's devastating impact. #PICIatASCO #ASCO2025 (3/3)
Dr. Knudsen bridges academia, industry & philanthropy, driving innovations from lab to clinic. With leadership roles at Sidney Kimmel Cancer Center, @americancancersoc.bsky.social & PICI, @drkarenknudsen.bsky.social al exemplifies how bold science & visionary leadership can accelerate cures. (2/3)
May 31, 2025 at 2:49 PM
Dr. Knudsen bridges academia, industry & philanthropy, driving innovations from lab to clinic. With leadership roles at Sidney Kimmel Cancer Center, @americancancersoc.bsky.social & PICI, @drkarenknudsen.bsky.social al exemplifies how bold science & visionary leadership can accelerate cures. (2/3)
With 300+ publications and a commitment to accelerating therapies, @drkarenknudsen.bsky.social has built bridges across academia, industry and philanthropy.
Thank you for your dedication to ending cancer’s devastating impact.
🕘 Sat, 9:45 AM CT | Hall B1
🔗 www.parkerici.org/the-latest/a...
Thank you for your dedication to ending cancer’s devastating impact.
🕘 Sat, 9:45 AM CT | Hall B1
🔗 www.parkerici.org/the-latest/a...
ASCO 2025: In a Defining Era for Oncology, PICI Drives Patient Impact Forward - Parker Institute for Cancer Immunotherapy
PICI’s contributions at ASCO 2025 span more than 50 presentations, including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only...
www.parkerici.org
May 31, 2025 at 1:07 AM
With 300+ publications and a commitment to accelerating therapies, @drkarenknudsen.bsky.social has built bridges across academia, industry and philanthropy.
Thank you for your dedication to ending cancer’s devastating impact.
🕘 Sat, 9:45 AM CT | Hall B1
🔗 www.parkerici.org/the-latest/a...
Thank you for your dedication to ending cancer’s devastating impact.
🕘 Sat, 9:45 AM CT | Hall B1
🔗 www.parkerici.org/the-latest/a...
Targets EGFRvIII & deploys TEAM antibodies at wild‑type EGFR—early traction against GBM heterogeneity.
Explore more PICI Network highlights: www.parkerici.org/the-latest/a...
#PICIatASCO #CancerImmunotherapy (2/2)
Explore more PICI Network highlights: www.parkerici.org/the-latest/a...
#PICIatASCO #CancerImmunotherapy (2/2)
May 30, 2025 at 10:23 PM
Targets EGFRvIII & deploys TEAM antibodies at wild‑type EGFR—early traction against GBM heterogeneity.
Explore more PICI Network highlights: www.parkerici.org/the-latest/a...
#PICIatASCO #CancerImmunotherapy (2/2)
Explore more PICI Network highlights: www.parkerici.org/the-latest/a...
#PICIatASCO #CancerImmunotherapy (2/2)